Histopathologic diagnosis of cervical biopsies determines clinical management of patients with an abnormal cervical cancer-screening test yet is prone to poor interobserver reproducibility. Immunohistochemical staining for biomarkers related to the different stages of cervical carcinogenesis may provide objective standards to reduce diagnostic variability of cervical biopsy evaluations but systematic, rigorous evaluations of their potential clinical utility are lacking. To address diagnostic utility of human papillomavirus (HPV) L1, p16INK4a, and Ki-67 immunohistochemical staining for improving diagnostic accuracy, we conducted a community-based and population-based evaluation using 1455 consecutive cervical biopsies submitted to the Department of Pathology at the University of Virginia during a period of 14 months. Thin-sections of each biopsy from 1451 of 1455 (99.7%) biopsies underwent evaluation of immunohistochemical stains for the 3 biomarkers, masked to the original diagnosis, and the results were compared with an adjudicated, consensus diagnosis by 3 pathologists. p16INK4a immunostaining, using the strongest staining as the cutpoint, was 86.7% sensitive and 82.8% specific for cervical intraepithelial neoplasia (CIN) grade 2 or more severe (CIN2+) diagnoses. The performance of p16INK4a was more sensitive (P<0.001), less specific (P<0.001), and of similar overall accuracy for CIN2+ compared with the combined performance of all pathologist reviews in routine clinical diagnostic service (sensitivity=68.9%, specificity=97.2%). Ki-67 immunostaining was also strongly associated with a CIN2+ diagnosis but its performance at all staining intensities was inferior to p16INK4a immunostaining, and did not increase the accuracy of CIN2+ diagnosis when combined with p16INK4a immunostaining compared with p16INK4a immunostaining alone. We found no utility for L1 immunostaining in distinguishing between CIN and non-CIN. In conclusion, with a rigorous evaluation, we found immunohistochemical staining for p16INK4a to be a useful and reliable diagnostic adjunct for distinguishing biopsies with and without CIN2+.
*Robert E. Fechner Laboratory of Surgical Pathology, University of Virginia Health System, Charlottesville, VA
†Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD
Dr Castle was supported by the Intramural Research Program of the NIH, National Cancer Institute. Antibodies for the detection of p16INK4a were donated by mtm laboratories AG (Heidelberg, Germany) and for the detection of L1 capsid protein by Cytoimmun Diagnostics (Pirmasens, Germany). Dr Stoler serves as consultant for mtm laboratories. In addition, Dr Stoler has been a consultant in clinical trial and HPV DNA test development for Third Wave, Hologic, Qiagen, Roche Molecular Systems, and Gen-Probe.
Correspondence: Mark H. Stoler, MD, Robert E. Fechner Laboratory of Surgical Pathology, University of Virginia Health System, 1215 Lee Street. HEP Room. 3032, Charlottesville, VA 22908-0214 (e-mail: firstname.lastname@example.org).